Diagnostic pathways for Hurler syndrome (MPS I-H)
Hurler syndrome (severe mucopolysaccharidosis type I, MPS I-H) is rare, but the route to diagnosis is often similar: a pattern of early symptoms, initial investigations, specialist referral, and confirmatory enzyme and genetic testing. Because early haematopoietic stem cell transplantation (HSCT) offers the best chance to preserve brain function, having clear diagnostic pathways helps families and healthcare professionals move from concern to confirmed diagnosis without unnecessary delay.
This page brings together the main diagnostic pathways for Hurler syndrome, including routes from clinical suspicion, newborn screening, and incidental findings, and explains who does what at each stage.
From first concern to specialist care
A diagnostic pathway is simply the sequence of steps and decisions that leads from the first sign of a problem to a confirmed diagnosis and an initial treatment plan. For Hurler syndrome, these pathways differ depending on how the condition is first suspected:
- A baby or toddler with early signs and multisystem involvement.
- A newborn flagged by screening.
- A child or teenager investigated for another problem, where MPS I is picked up incidentally.
Understanding these routes helps families know what to expect and helps clinicians know when and how to escalate.
The three main entry points to diagnosis
You can visualise the diagnostic pathways as three “front doors”:
Symptom-based pathway
Newborn screening pathway
Incidental / later presentation pathway
An older child or teenager is investigated for skeletal, cardiac or ENT problems, and the combination of findings prompts consideration of MPS I.
Each of these then converges onto the same set of confirmatory biochemical and genetic tests, followed by severity assessment and referral for treatment.
Pathway from clinical suspicion in a symptomatic child
First concerns
Parents or clinicians notice multiple issues: hernias, big tummy, recurrent infections, coarse features, noisy breathing, joint stiffness, delayed milestones. The child may be seen in primary care, general paediatrics, ENT, orthopaedics or neurology.
Pattern recognition and initial referral
A clinician joins the dots and suspects an inherited metabolic or storage disorder, such as MPS. Referral is made to a regional metabolic / genetics service, ideally marked as urgent.
Baseline investigations
At local or regional level, initial tests may include:
- Urine glycosaminoglycans (GAGs)
- Abdominal ultrasound (liver/spleen)
- Echocardiogram (valves, function)
- Skeletal survey (dysostosis multiplex)
- Basic blood tests and any required imaging for symptom control
Specialist metabolic assessment
The metabolic team takes a detailed history, examines the child and reviews all available tests. If MPS I is suspected, they arrange IDUA enzyme assay and IDUA gene sequencing.
Confirmation and severity classification
Very low or absent IDUA activity plus biallelic pathogenic IDUA variants confirms MPS I. The team then assesses whether the child has severe MPS I-H or an attenuated form, using age at onset, development, somatic burden and genotype.
Treatment pathway
For severe MPS I-H, early referral for HSCT assessment (often with ERT as bridging/supportive therapy). For attenuated MPS I, an ERT-based pathway and long term monitoring.
Pathway after a positive newborn screening result
For babies in regions where MPS I is on the newborn screening panel:
Screen positive report
The screening lab identifies low IDUA activity in the dried blood spot. Internal second-tier tests may already be done (repeat IDUA, GAG markers, sometimes rapid IDUA genotyping).
Family contact and first explanation
The newborn screening / local paediatric team contacts the parents promptly. They explain that this is not yet a diagnosis, but further tests are needed.
Confirmatory testing and specialist referral
Confirmatory tests are arranged urgently, typically:
- IDUA enzyme assay in leukocytes or plasma
- Urine GAGs
- Full IDUA gene sequencing if not already done
The baby is referred to a metabolic centre for clinical assessment.
Phenotype prediction and severity assessment
The metabolic team reviews:
- Which IDUA variants are present (known severe vs attenuated vs novel)
- How low the enzyme activity is
- GAG pattern
- Any early clinical signs at examination
If the profile strongly indicates severe MPS I-H, the child is classed as "likely Hurler" even before significant symptoms appear.
Time-critical decision-making
The baby is referred quickly to a transplant centre to discuss HSCT, often within the first months of life. ERT may be started while decisions are made and work-up is completed. Babies with attenuated/uncertain phenotypes are followed closely with planned reviews and repeat testing.
Pathway for older children and teens
In regions without newborn screening, and even in screened regions, some children with MPS I (including occasionally severe phenotypes that were missed or misclassified) may first come to attention later in childhood or adolescence.
Common scenarios:
- Orthopaedic referral for hip dysplasia, spinal deformity, genu valgum or short stature
- Cardiology referral for valve disease discovered on routine exam
- ENT clinic for recurrent otitis media, hearing loss and sleep apnoea
- Developmental paediatrics for learning difficulties plus physical differences
Pathway steps:
- Specialist recognises that the pattern is not typical for isolated orthopaedic/ENT/cardiac disease
- Referral is made to a metabolic / genetics service for possible storage disorder
- Diagnostic work-up mirrors the symptomatic child pathway: urine GAGs, enzyme assay, IDUA sequencing, etc
- Once MPS I is confirmed, severity is assessed
- Treatment decisions reflect the age and existing organ involvement – HSCT may or may not still be appropriate; ERT and supportive care are central